Marjan Azin

Marjan Azin

Auto-generated profile, based on publicly available information

Marjan Azin

Center for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MHMei Huang
Mei Huang
DWDongyao Wang
Dongyao Wang
JHJiao Huang
Jiao Huang
ABAn-Na Bae
An-Na Bae
YXYun Xia
Yun Xia
SDShadmehr Demehri
Shadmehr Demehri
Hepatitis B virus (HBV) infection is associated with hepatitis and hepatocellular carcinoma (HCC). Considering that most HBV-infected individuals remain asymptomatic, the mechanism linking HBV to hepatitis and HCC remains uncertain. Herein, we demonstrate that HBV alone does not cause liver inflammation or cancer. Instead, HBV alters the chronic inflammation induced by chemical carcinogens to promote liver carcinogenesis. Long-term HBV genome expression in mouse liver increases liver inflammation and cancer propensity caused by a carcinogen, diethylnitrosamine (DEN). HBV plus DEN-activated interleukin-33 (IL-33)/regulatory T cell axis is required for liver carcinogenesis. Pitavastatin, an IL-33 inhibitor, suppresses HBV plus DEN-induced liver cancer. IL-33 is markedly elevated in HBV+ hepatitis patients, and pitavastatin use significantly correlates with reduced risk of hepatitis and its associated HCC in patients. Collectively, our findings reveal that environmental carcinogens are the link between HBV and HCC risk, creating a window of opportunity for cancer prevention in HBV carriers.

7 November 2024 in JID Innovations
Verified
Journal Article
Open access
TOTomonori Oka
Tomonori Oka
THTatsuya Hasegawa
Tatsuya Hasegawa
TLTruelian Lee
Truelian Lee
VOValeria S. Oliver-Garcia
Valeria S. Oliver-Garcia
MMMahsa Mortaja
Mahsa Mortaja
SDShadmehr Demehri
Shadmehr Demehri
Adult human skin contains nearly twice as many T cells as the peripheral blood, which include tissue-resident memory T cells. However, the precise mechanisms maintaining tissue-resident memory T cells in the healthy skin remain unclear. Using normal human skin samples, we find that Langerhans cells (LCs) contact T cells in the epidermis of the elderly. LCs with high HLA-II, CD86, and PD-L2 expression directly contacted PD-1+ tissue-resident memory T cells and CTLA-4+ regulatory T cells in the epidermis, indicating an axis of peripheral tolerance in a steady state. Environmental insults, UVB radiation, and hapten downregulated HLA-II and CD86 on LCs in the epidermis, suggesting that disruption of LC–T cell tolerogenic axis contributes to skin inflammation. Interestingly, immune checkpoint blockade therapy was associated with decreased epidermal LC–T cell contact in the normal skin of patients with cancer affected by cutaneous immune-related adverse events. Collectively, our findings indicate that LCs may contribute to T cell tolerance in the epidermis.

29 January 2022 in JID Innovations
Verified
Journal Article
Open access
MAMarjan Azin
Marjan Azin
AMAndrew B. Mahon
Andrew B. Mahon
SISteven Isaacman
Steven Isaacman
JSJulia E. Seaman
Julia E. Seaman
IAIsabel E. Allen
Isabel E. Allen
SDShadmehr Demehri
Shadmehr Demehri

4 February 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MAMarjan Azin
Marjan Azin
SDShadmehr Demehri
Shadmehr Demehri

11 August 2023 in JID Innovations
Verified
Journal Article
Open access
MAMarjan Azin
Marjan Azin
KNKenneth H. Ngo
Kenneth H. Ngo
JHJennet Hojanazarova
Jennet Hojanazarova
SDShadmehr Demehri
Shadmehr Demehri
Nonkeratinocyte cutaneous malignancies, including breast cancer cutaneous metastasis and melanoma in situ, are often poor surgical candidates. Imiquimod (IMQ), a toll-like receptor 7 agonist that activates innate immunity in the skin, is used to treat these cutaneous malignancies. However, IMQ's modest effect on the activation of adaptive immunity limits its efficacy as a monotherapy. In this study, we demonstrate that topical TSLP cytokine inducers—calcipotriol and retinoic acid—synergize with IMQ to activate CD4+ T-cell immunity against nonkeratinocyte cutaneous malignancies. Topical calcipotriol plus IMQ treatment reduced breast tumor growth compared with calcipotriol or IMQ alone (P < 0.0001). Calcipotriol plus IMQ–mediated tumor suppression was associated with significant infiltration of CD4+ effector T cells in the tumor microenvironment. Notably, topical calcipotriol plus IMQ immunotherapy enabled immune checkpoint blockade therapy to effectively control immunologically cold breast tumors, which was associated with induction of CD4+ T-cell immunity. Topical treatment with calcipotriol plus IMQ and retinoic acid plus IMQ also blocked subcutaneous melanoma growth. These findings highlight the synergistic effect of topical TSLP induction in combination with innate immune cell activation as an effective immunotherapy for malignancies affecting the skin.

1 October 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MAMarjan Azin
Marjan Azin
SDShadmehr Demehri
Shadmehr Demehri